Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics, Inc. (TARA)
Company Research
Source: GlobeNewswire
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the grant of inducement non-qualified stock options to purchase an aggregate of 118,400 shares of common stock to Lisa Schlesinger, Protara’s newly appointed Vice President, Head of New Product Development and Market Access. Each stock option has an exercise price per share equal to $2.23 per share, Protara’s closing trading price on June 24, 2024, the grant date, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and 1/36th of the underlying shares vesting monthly thereafter over 36 months subject to Ms. Schlesinger's continued service relationship with Protara through the applicable vesting dates. The independent members of Protara’s Board of Directors approved the award as an inducement material to M
Show less
Read more
Impact Snapshot
Event Time:
TARA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARA alerts
High impacting Protara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TARA
News
- Vascular Malformations Market to Grow Substantially by 2034, Assesses DelveInsight | Key Companies - ARTham Therapeutics, Neurelis, Protara Therapeutics, Recursion, Genentech, Vascular Therapies, Palvella Therapeutics [Yahoo! Finance]Yahoo! Finance
- Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- ASTS, CRBU and DOMO are among after hour movers [Seeking Alpha]Seeking Alpha
- Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation SummitGlobeNewswire
- UK NICE backs Exact's Oncotype cancer genomic test Fri, May 10, 2024, 3:22 PM GMT+2 2 min read 0 In this article: Advertisement Up next These 2 ‘Strong Buy' Penny Stocks Could Surge Over 400%, Says Oppenheimer Thu, May 9, 2024, 7:20 PM GMT+2 6 min read Acquire Media Monitor
TARA
Earnings
- 5/2/24 - Beat
TARA
Sec Filings
- 6/28/24 - Form 4
- 6/27/24 - Form 4
- 6/10/24 - Form 4
- TARA's page on the SEC website